A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.

MLA

Pastores, Gregory M., et al. “A Phase 3, Multicenter, Open-Label, Switchover Trial to Assess the Safety and Efficacy of Taliglucerase Alfa, a Plant Cell-Expressed Recombinant Human Glucocerebrosidase, in Adult and Pediatric Patients with Gaucher Disease Previously Treated with Imiglucerase.” Blood Cells, Molecules & Diseases, vol. 53, no. 4, Dec. 2014, pp. 253–60. EBSCOhost, https://doi.org/10.1016/j.bcmd.2014.05.004.

APA

Pastores, G. M., Petakov, M., Giraldo, P., Rosenbaum, H., Szer, J., Deegan, P. B., Amato, D. J., Mengel, E., Tan, E. S., Chertkoff, R., Brill-Almon, E., & Zimran, A. (2014). A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells, Molecules & Diseases, 53(4), 253–260. https://doi.org/10.1016/j.bcmd.2014.05.004

Chicago

Pastores, Gregory M, Milan Petakov, Pilar Giraldo, Hanna Rosenbaum, Jeffrey Szer, Patrick B Deegan, Dominick J Amato, et al. 2014. “A Phase 3, Multicenter, Open-Label, Switchover Trial to Assess the Safety and Efficacy of Taliglucerase Alfa, a Plant Cell-Expressed Recombinant Human Glucocerebrosidase, in Adult and Pediatric Patients with Gaucher Disease Previously Treated with Imiglucerase.” Blood Cells, Molecules & Diseases 53 (4): 253–60. doi:10.1016/j.bcmd.2014.05.004.